NCT02152059View on ClinicalTrials.gov

A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2014

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Small Cell Lung CancerPlatinum-sensitive
Interventions
DRUG

BIBF1120

BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor

Trial Locations (1)

T6G 1Z2

Cross Cancer Institute, Edmonton

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Cross Cancer Institute

OTHER

collaborator

Boehringer Ingelheim

INDUSTRY

lead

AHS Cancer Control Alberta

OTHER

NCT02152059 - A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy | Biotech Hunter | Biotech Hunter